A method of treating or preventing Parkinson's disease in a subject using the readthrough isoenzyme of acetylcholinesterase is described. The enzyme is processed to remove the N-terminal extension. This isoenzyme ameliorates the effects of dopaminergic neurotoxins and acetylcholinesterase inhibitors in a mouse model of Parkinson's disease. Exposure of Parkinson's disease mice to the dopaminergic neurotoxin MPTP resulted in major changes in the levels in expression of genes assocd. with alternative RNA splicing. These changes were limited in mice overexpressing the gene for the readthrough isoenzyme.
I pulled it off of a scifinder search, which is a database run by the American chemical society. I'm pretty sure you have to be a member, but you might be able to use the filing number to check a public database.